Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press58010.17650/1726-9776-2016-12-2-84-91PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫIntermediate results of the observational program on the Eligard (45 mg) administration in the clinical practiceПромежуточные результаты многоцентровой наблюдательной программы по применению препарата Элигард 45 мг в клинической практикеMatveevV. B.МатвеевВ. Б.
Russian Federation
MarkovaA. S.МарковаА. С.
Russian Federation
mark-an1@ya.ruN.N. Blokhin Russian Cancer Research CenterФГБУ «РОНЦ им. Н.Н. Блохина» Минздрава России23 Kashirskoe Shosse, Moscow, 115478, RussiaРоссия, 115478, Москва, Каширское шоссе, 233006201612284912406201624062016https://oncourology.abvpress.ru/oncur/article/view/580

This article deals with the intermediate results of the multicentral observational program on the 6-month prodrug leuprorelin acetate (Eligard 45 mg) administration. The study objective is to confirm the efficiency and safety of the Eligard 45 mg administration in patients with the prostate cancer in the clinical practice of the oncourology specialists in Russia. In 12 months of the hormone therapy with the Eligard 45 mg there was the clinically relevant decrease of the prostatic specific antigen (PSA) levels secondary to the appropriate suppression of the testosterone level lower than the castration one < 20 ng / dl. The PSA level decreased, at an average, on 82 % (from 41.4 to 7.65 ng / ml). In 89 % of patients, treated with Eligard 45 mg, the testosterone level was < 20 ng / dl. The patients», treated with Eligard 45 mg, quality of life analysis showed the improvement of this criteria in the course of the treatment. Thus, intermediate results of the multicentral observational program, proved the favorable tolerability and efficiency of the 6-month prodrug Eligard 45 mg towards the PSA and testosterone serum levels suppression in the routine clinical practice in prostate cancer patients.

В данной статье представлены промежуточные результаты многоцентровой наблюдательной программы по применению 6-месячной депо-формы лейпрорелина ацетата (Элигард 45 мг). Основная цель исследования – подтверждение эффективности и безопасности препарата Элигард 45 мг у больных раком предстательной железы (РПЖ) в рутинной клинической практике российских онкоурологов. Через 12 мес гормональной терапии препаратом Элигард 45 мг у большинства пациентов было достигнуто значимое снижение уровня простатического специфического антигена (ПСА) на фоне адекватной супрессии уровня тестостерона ниже кастрационного значения 20 нг / дл. Уровень ПСА в сыворотке крови снижался в среднем на 82 % (с 41,4 до 7,65 нг / мл). Уровень тестостерона < 20 нг / дл был достигнут у 89 % больных, получавших препарат Элигард 45 мг. Анализ качества жизни пациентов с РПЖ, проходящих терапию препаратом Элигард 45 мг, показал улучшение данного показателя на фоне лечения. Таким образом, промежуточные результаты многоцентровой наблюдательной программы подтверждают хорошую переносимость и эффективность 6-месячной депо-формы препарата Элигард 45 мг в отношении супрессии уровней ПСА и тестостерона в сыворотке крови в рутинной клинической практике у больных РПЖ.

prostate cancerhormone therapytestosteroneprostate specific antigenluteinising hormone-releasing hormone agonistsleuprorelin acetateEligardрак предстательной железыгормональная терапиятестостеронпростатический специфический антигенагонисты лютеинизирующего гормона рилизинг-гормоналейпрорелина ацетатЭлигард1. Состояние онкологической помощи в 2014 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2015. 236 с. [Cancer care status in 2014. Eds. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow: P.A. Herzen МSROI, 2015. 236 p. (In Russ.)].Состояние онкологической помощи в 2014 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена, 2015. 236 с. [Cancer care status in 2014. Eds. by: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Мoscow: P.A. Herzen МSROI, 2015. 236 p. (In Russ.)].2. Guidelines on Prostate Cancer. European Association of Urology (EAU). 2015. 137 p.Guidelines on Prostate Cancer. European Association of Urology (EAU). 2015. 137 p.3. Eisenberger M.A., Blumenstein B.A., Crawford E.D. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339(15):1036–42.Eisenberger M.A., Blumenstein B.A., Crawford E.D. et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339(15):1036–42.4. Akaza H., Hinotsu S., Usami M. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, doubleblind, randomized study for survival. Cancer 2009;115(15):3437–45.Akaza H., Hinotsu S., Usami M. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer: long-term follow-up of a phase 3, doubleblind, randomized study for survival. Cancer 2009;115(15):3437–45.5. Schmitt B., Bennett C., Seidenfeld J. et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000;(2):CD001526.Schmitt B., Bennett C., Seidenfeld J. et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev 2000;(2):CD001526.6. Tsushima T., Nasu Y., Saika T. et al. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol Int 2001;66(3):135–9.Tsushima T., Nasu Y., Saika T. et al. Optimal starting time for flutamide to prevent disease flare in prostate cancer patients treated with a gonadotropin-releasing hormone agonist. Urol Int 2001;66(3):135–9.7. Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, openlabel, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11): 1531–8.Klotz L., Boccon-Gibod L., Shore N.D. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, openlabel, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102(11): 1531–8.8. Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566–77.Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566–77.9. Hedlund P.O., Damber J.E., Hagerman I. et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42(3):220–9.Hedlund P.O., Damber J.E., Hagerman I. et al. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2008;42(3):220–9.10. Crawford E.D., Moul J.W., Sartor O., Shore N.D. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin. Drug Metab. Toxicol 2015;11(9):1465–74.Crawford E.D., Moul J.W., Sartor O., Shore N.D. Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl. Expert Opin. Drug Metab. Toxicol 2015;11(9):1465–74.11. Oefelein M.G., Feng A., Scolieri M.J. et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56(6): 1021–4.Oefelein M.G., Feng A., Scolieri M.J. et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56(6): 1021–4.12. Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10): 983–92.Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10): 983–92.13. Ryan C.J., Smith M.R., Fizazi K. et al. Final overall survival (OS) analysis of COUAA- 302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients without prior chemotherapy. Ann Oncol 2014;25:iv255–79.Ryan C.J., Smith M.R., Fizazi K. et al. Final overall survival (OS) analysis of COUAA- 302, a randomized phase 3 study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients without prior chemotherapy. Ann Oncol 2014;25:iv255–79.14. Klotz L., O’Callaghan C., Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151–6.Klotz L., O’Callaghan C., Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151–6.15. Hussain M., Tangen C.M., Higano C. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic rostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984–90.Hussain M., Tangen C.M., Higano C. et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic rostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984–90.16. Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175(2): 533–6.Crawford E.D., Sartor O., Chu F. et al. A 12-month clinical study of LA-2585 (45.0 mg): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2006;175(2): 533–6.17. Tunn U.W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urol 2011;11:15.Tunn U.W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urol 2011;11:15.18. Braeckman J., Michielsen D. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo- Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study. Arch Med Sci 2014;10(3);477–83.Braeckman J., Michielsen D. Efficacy and tolerability of 1- and 3-month leuprorelin acetate depot formulations (Eligard®/Depo- Eligard®) for advanced prostate cancer in daily practice: a Belgian prospective non-interventional study. Arch Med Sci 2014;10(3);477–83.